One adult's low-grade glioma had a rare gene change, and targeted treatment helped
Original title: Adult Low-Grade Glioma With MEF2D::NTRK1 Fusion: A Case Report and Literature Review.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This is a report on a single patient, not a study testing a treatment in a group of people.
The short version
Doctors found a rare gene fusion in one adult's slow-growing brain tumor, and a drug aimed at that gene helped him.
What was studied. This is a report on one patient, a 33-year-old adult with a low-grade glioma: A tumor that starts in the glial cells. Those are the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4. The grade says how the tumor is expected to act. See the glossary. Doctors looked at scans, tumor tissue, and gene tests to describe the tumor in detail.
What they found. The tumor looked slow-growing under the microscope. But it had spread widely in the brain, into the corpus callosum, the third ventricle, the whole front base of the skull, and the space above the pituitary. Gene testing found a MEF2D::NTRK1 fusion and a loss called 22q loss, with no other changes found. The patient was given a treatment aimed at NTRK, and the report says he benefited from it.
What this means, and what it doesn't
What it could mean: Gene testing can find a change in a brain tumor that points to a specific drug. This fusion had only been reported in faster-growing tumors before, so it may also show up in slow-growing ones in adults. If you have a glioma: A tumor that starts in the glial cells. Those are the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4. The grade says how the tumor is expected to act. See the glossary, it is fair to ask your doctor whether gene testing was done and what it showed.
What it doesn't mean: This is one patient, not a trial. One person doing well does not show that a drug works for others. There is no way to know from this report how long the benefit lasted. This is not a cure, and it does not change standard care for most people. NTRK drugs are only an option when testing finds that kind of gene change.
Source: PubMed, October 7, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.